Bristol Myers Squibb UK and Ireland


Our response to the global COVID-19 pandemic

As the COVID-19 situation rapidly evolves, Bristol Myers Squibb (BMS) is focused on:



Supporting global relief efforts

Protecting the health and safety of our workforce



Supply of Our Medicines



Ensuring our medicines get to patients without disruption or delay, by:

- Developing innovative solutions for transport of products and raw materials
 - Ensuring no interruption in our clinical or commercial supply chain

Continual supplies of our medicines for patients

 Globally engaging policymakers, key policy stakeholders and trade associations to ensure patients can continue to access their medicines

Workplace and Community



Keeping BMS employees healthy, safe and supported so they can continue to meet the needs of our patients, through:

- Mandatory work from home policy for employees, contingent workers and contractors
- Increased protection for essential employees that must work on site (e.g. production and distribution)



 Aligning with government guidance regarding travel restrictions and remote working



Global Relief Efforts



- · Licensed healthcare professional colleagues are being supported as they volunteer to support the NHS in this critical time
- Over 3,000 colleagues in the UK, US and Australia have registered with the BMS Skills2Give programme, to volunteer virtually with thousands of nonprofit organisations
- Targeted donations of PPE and other equipment have been made to help local communities across the globe





support recovery of NHS cancer services, charities and patient groups affected by COVID-19 across the UK and Ireland



effective support can reach communities suffering during this crisis



To assist the National Ambulance Service and provide highly trained volunteers as emergency medical technicians in ambulances

Contribution to Research. **Life-Sciences Industry**



We are...

- Working with researchers, the biotech community and the broader life sciences industry on ways to accelerate therapies for COVID-19
- Collaborating with cross-industry groups to support COVID-19 research

